Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) [Phase 3]

View source ↗

Summary

A Phase 3 trial (ENLIGHTEN-Fibrosis) is ongoing to evaluate the efficacy and safety of Pegozafermin in participants with metabolic dysfunction-associated steato…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatotic Liver Disease
• Nonalcoholic Steatohepatitis with Fibrosis

Drugs mentioned

• Pegozafermin (pegozafermin)

Snippet

Sponsor: 89bio, Inc. | Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis | Phase 3 | Status: RECRUITING